Glen Weiss to Antimetabolites, Antineoplastic
This is a "connection" page, showing publications Glen Weiss has written about Antimetabolites, Antineoplastic.
Connection Strength
1.069
-
Dearing KR, Weiss GJ. Molecular characterization may be of PARAMOUNT importance. J Clin Oncol. 2014 Feb 10; 32(5):481-2.
Score: 0.417
-
Mahadevan D, Chalasani P, Rensvold D, Kurtin S, Pretzinger C, Jolivet J, Ramanathan RK, Von Hoff DD, Weiss GJ. Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. Am J Clin Oncol. 2013 Jun; 36(3):239-43.
Score: 0.400
-
Weiss GJ, Langer C, Rosell R, Hanna N, Shepherd F, Einhorn LH, Nguyen B, Paul S, McAndrews P, Bunn PA, Kelly K. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2006 Sep 20; 24(27):4405-11.
Score: 0.252